Lysine-specific demethylase
1 (LSD1 or KDM1A) is a chromatin modifying
enzyme playing a key role in the cell cycle and cell differentiation
and proliferation through the demethylation of histones and nonhistone
substrates. In addition to its enzymatic activity, LSD1 plays a fundamental
scaffolding role as part of transcription silencing complexes such
as rest co-repressor (CoREST) and nucleosome remodeling and deacetylase
(NuRD). A host of classical amine oxidase inhibitors such as tranylcypromine,
pargyline, and phenelzine together with LSD1 tool compounds such as
SP-2509 and GSK-LSD1 have been extensively utilized in LSD1 mechanistic
cancer studies. Additionally, several optimized new chemical entities
have reached clinical trials in oncology such as ORY-1001 (iadademstat),
GSK2879552, SP-2577 (seclidemstat), IMG-7289 (bomedemstat), INCB059872,
and CC-90011 (pulrodemstat). Despite this, no single study exists
that characterizes them all under the same experimental conditions,
preventing a clear interpretation of published results. Herein, we
characterize the whole LSD1 small molecule compound class as inhibitors
of LSD1 catalytic activity, disruptors of SNAIL/GFI1 (SNAG)-scaffolding
protein–protein interactions, inducers of cell differentiation,
and potential anticancer treatments for hematological and solid tumors
to yield an updated, unified perspective of this field. Our results
highlight significant differences in potency and selectivity among
the clinical compounds with iadademstat being the most potent and
reveal that most of the tool compounds have very low activity and
selectivity, suggesting some conclusions derived from their use should
be taken with caution.